Please ensure Javascript is enabled for purposes of website accessibility
Jim Crumly

Jim Crumly


Jim bought his first stocks in 1967 with paper route money and has been invested in equities ever since. He's still learning, though, and enjoys studying and investing in a wide variety of businesses. He has a BS and MS in electrical engineering from Stanford University, and retired after 34 years with a large technology company.

Recent articles


3 Great Stocks for Low-Risk Investors

These companies with low-risk businesses will hold up over the long run.


3 Healthcare Stocks I'd Buy Right Now

Two innovative small companies with scorching growth and one bargain biotech.


3 Absurdly Cheap Coronavirus Stocks to Buy Now

These stocks would be buys even without the pandemic.


What the COVID-19 Variants Mean for Vaccine Makers

This risk to public health is causing a strategic shift by the various developers.


Jazz Pharmaceuticals to Acquire Cannabis Drug Company

The deal to buy GW Pharmaceuticals creates a leader in neuroscience.


Johnson & Johnson Says Its One-Dose Coronavirus Vaccine Was 66% Effective in Clinical Trial

The vaccine was 100% effective in preventing hospitalization and death from COVID-19.


Could This Drug Be 100% Effective in Preventing Symptomatic COVID-19 Infections?

Strong interim trial data boosts the prospects for a treatment already worth billions.


Merck Gives Up on Coronavirus Vaccines

The company will focus on antiviral and anti-inflammatory treatments for patients infected with COVID-19.


Moderna Says Vaccine Protects Against All Known Variants

A weaker response to the South African variant prompts studies of a strain-specific booster.


Pfizer and BioNTech Report Evidence That Their Vaccine Is Effective Against COVID-19 Variant

A new study bolsters confidence in the mRNA vaccine.


Where Will Innovative Industrial Properties Be in 5 Years?

Can this profitable marijuana company keep up its winning streak?


Quidel Rapid Antigen Test for COVID-19 Wins Authorization

A new point-of-care test is both fast and accurate.


3 Top Mid-Cap Stocks to Buy Now

These companies are succeeding during the pandemic and will perform even better during a recovery.


Forget the Vaccine. Here Are the Real Reasons AstraZeneca Stock Is a Buy

The market isn't focused on the real story with this stock. That will change.


3 Top Pharma Stocks to Buy Now

Investors are shunning these stocks now, but that will change.


DexCom Has a Lot to Prove in 2021

Investors have a few questions as the company faces increasing competition.


Should You Sell Teladoc Health Stock As Coronavirus Vaccines Succeed?

Investors are worried that Teledoc Health stock will fade along with the pandemic.


Is AbbVie a Great Dividend Stock?

The stock has a high yield -- and it also has something even more important.


3 Bargain Stocks You Can Buy Today

Investors have been selling these stocks, but patient investors should take advantage of the opportunity.


This Small-Cap Stock Will Be a Long-Term Winner From the Pandemic

Wall Street seems worried that the arrival of coronavirus vaccines will take the wind out of the sails of this genetic and medical testing company. That view misses the big picture.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.